Sino-Singapore Online, May 6 (Chen Jing) Efavirenz, Tenofovir, and Lamivudine "cocktail" combination is the most widely used antiviral treatment program for HIV-infected people in China.
Led by Professor Lu Hongzhou of Shanghai Public Health Clinical Center, together with Nanjing Second Hospital and Yunnan Provincial Infectious Disease Hospital, a research team was established to confirm that the anti-AIDS treatment plan of efavirenz and tenofovir reduction in Chinese AIDS The effectiveness of such a program is safer.
China's related research on the reduction of efavirenz has not been reported before. The research results were published in the internationally renowned journal "Emerging Microbes & Infections". Lu Hongzhou said that this shows that the reduction of efavirenz in Chinese HIV-infected people is worth promoting and has important significance. The study provides more evidence for reducing the use of efavirenz in China.
In the treatment of AIDS in Chinese patients, efavirenz has adverse reactions to the nervous system, such as dizziness, dreaminess, poor sleep, depression, etc .; nephrotoxicity and bone toxicity caused by tenofovir have brought many Bothered. In fact, there is an international consensus on the reduction of efavirenz, but there is a lack of data from randomized controlled clinical studies in the Chinese population. Prior to this, the international medical community has not attempted to reduce tenofovir. Lu Hongzhou told reporters that doctors and patients are generally concerned that reducing the amount of anti-AIDS drugs will affect their antiviral efficacy and will increase the risk of drug resistance.
In response to this problem, Professor Lu Hongzhou's team led the design of a multi-center, prospective, randomized controlled clinical study to explore whether the combined anti-viral regimen of lamivudine can be The reduction of poison does not reduce the effect. " The researchers used a reduced version of the "cocktail" combination in infected people who had never received HIV antiviral treatment.
After 48 weeks of treatment in the reduction group and the standard treatment group, by comparing their adverse reactions and efficacy, the researchers determined that the antiviral effect of the reduction group was equivalent to the standard group, and the total adverse reactions were significantly reduced.
Studies have shown that in the reduction group, efavirenz has fewer adverse reactions to the nervous system and fewer digestive systems; however, tenofovir-related renal damage and bone density decrease have no difference between the two groups. The researchers found that the risk of resistance in the reduced group did not increase. (Finish)